Everest Medicines Limited
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline produc…
Biotechnology
CN, Shanghai [HQ]
Cash Flow Statement
6 Sheets · From 2023 to 2018Configuration
In Million CNY. Margins, Growth Rates In %
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Operating Cash Flow (OCF) | -106.00 | -88.00 | -471.00 | -729.00 | -1,155.00 | -769.00 | |
| Operating Cash (Net) | -106.00 | -88.00 | -471.00 | -729.00 | -1,155.00 | -769.00 | |
| Accounts Receivable | - - | - - | - - | - - | -5.00 | -44.00 | |
| Accounts Payable | - - | - - | - - | - - | 5.00 | - - | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | |
| Change | -2.00 | 84.00 | 75.00 | 34.00 | -29.00 | -81.00 | |
| Other WC | - - | 84.00 | 75.00 | 34.00 | -18.00 | 87.00 | |
| Investing Activities | |||||||
| Used Cash (Net) | -406.00 | -47.00 | -519.00 | -975.00 | -1,028.00 | 752.00 | |
| Capital Expenditure | -211.00 | -93.00 | -519.00 | -975.00 | -432.00 | -265.00 | |
| Purchases of Investments | - - | - - | - - | - - | -1,160.00 | -3,533.00 | |
| Sale/Maturity of Investment | - - | - - | - - | - - | - - | 2,964.00 | |
| Property, Plant, Equipment (P&PE) | -211.00 | -93.00 | -519.00 | -975.00 | -432.00 | -265.00 | |
| Acquisitions (Net) | -194.00 | 45.00 | - - | - - | - - | - - | |
| Other Investing Activities | - - | -138.00 | -511.00 | -865.00 | 565.00 | 6.00 | |
| Financing Activities | |||||||
| Used Cash (Net) | -461.00 | -61.00 | -5,637.00 | -76.00 | -25.00 | -10.00 | |
| Debt Repayment | - - | -8.00 | -19.00 | -23.00 | -30.00 | -8.00 | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | - - | 64 | - - | - - | |
| Issued | 3.00 | - - | 3,735.00 | 5.00 | 5.00 | 29.00 | |
| Repurchased | - - | - - | - - | -58.00 | - - | - - | |
| Other Financing Activities | 458.00 | 70.00 | 1,922.00 | 23.00 | -25.00 | 21.00 | |
| Cash Balances | |||||||
| Begin of Period | 226.00 | 183.00 | 106.00 | 4,481.00 | 2,640.00 | 490.00 | |
| End of Period | 183.00 | 106.00 | 4,481.00 | 2,640.00 | 490.00 | 523.00 | |
| Change | -42.00 | -77.00 | 4,375.00 | -1,841.00 | -2,149.00 | 32.00 | |
| Non-Cash Balances | |||||||
| Depreciation and Amortization | 5.00 | 10.00 | 20.00 | 31.00 | 42.00 | 76.00 | |
| Stock Based Compensation | - - | 14.00 | 117.00 | 224.00 | 206.00 | 73.00 | |
| Other | 864.00 | 15.00 | 4,969.00 | -24.00 | -1,128.00 | -84.00 | |
| Highlighted metrics | |||||||
| Free Cash Flow (FCF) | -318.00 | -181.00 | -991.00 | -1,705.00 | -1,588.00 | -1,035.00 | |
| Cash Conversion Cycle (CCC) | - - | - - | - - | -533,605.00 | 47,383.00 | -173.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
|||||||
| Forex Effect on Cash | 9.00 | -3.00 | -270.00 | -58.00 | 59.00 | 38.00 |